Pfiz­er pub­lish­es clin­i­cal tri­al di­ver­si­ty da­ta from past decade, show­ing there's much work to be done

The pan­dem­ic turned a harsh spot­light on a his­toric lack of di­ver­si­ty in the bio­phar­ma in­dus­try. Now, in an ef­fort to fos­ter trans­paren­cy, Pfiz­er has pub­lished di­ver­si­ty da­ta from its clin­i­cal tri­als go­ing back 10 years, show­ing there’s much work to be done.

Be­tween 2011 and 2020, Black or African Amer­i­can par­tic­i­pants made up 14.3% of 212 tri­als for which da­ta on race was col­lect­ed, ac­cord­ing to Pfiz­er. To put that in per­spec­tive, Black Amer­i­cans rep­re­sent about 13.4% of the US pop­u­la­tion. But when bro­ken down by tri­al, on­ly about half of Pfiz­er’s stud­ies (56.1%) sur­passed cen­sus lev­els for Black par­tic­i­pants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.